All Articles

Facing delisting, Hong Kong-based PTL Limited enacts a massive 1-for-80 share consolidation. But can this financial maneuver fix deeper business issues?

New data on MCO-010 gene therapy identifies ideal patients for Retinitis Pigmentosa, a key step as the one-time injection advances toward FDA approval.

The partnership moves beyond compliance, integrating deep binary analysis with lifecycle management to provide continuous software risk intelligence for critical industries.

Target Hospitality is rapidly expanding workforce housing for AI data centers, revealing the massive, unseen physical infrastructure powering the tech revolution.

Penske Automotive's latest Florida acquisition highlights a fierce battle for the state's booming luxury car market, adding $450M in expected revenue.

After repeated hurricane shutdowns, St. Petersburg invests $1M in innovative flood panels to keep its critical water facilities running.

Cullinan Therapeutics heads to key investor conferences, ready to showcase its T-cell engager platform for both cancer and challenging autoimmune diseases.

As Ring Energy preps its Q4 results, investors eye debt reduction, cost control, and 2026 strategy amid a challenging Permian market.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.

Maiden drilling at West Santa Fe reveals significant near-surface gold, sparking speculation of a low-cost, open-pit mine in the prolific Walker Lane.

Swiss biotech AC Immune begins a human trial for an oral drug aiming to halt the chronic inflammation driving diseases like Alzheimer's and Parkinson's.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

With no approved therapies for Hepatitis E, Atea Pharmaceuticals' new drug shows potent preclinical results, offering a potential lifeline for vulnerable patients.

Cell and gene therapy manufacturer OXB posts a dramatic turnaround to profitability, with surging revenues and an ambitious forecast for the coming years.

Blueprint Capital Advisors' new list of 'Active Icons' honors industry giants not just for wealth, but for their commitment to shaping a more inclusive future.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

With its Moda-flx system cleared by the FDA, Diality hires M&A expert Peter Donato to navigate the path to commercialization in the $92B dialysis market.

The shipping and printing giant's spot on a top global list highlights a stable model for entrepreneurs and its vital role in supporting small businesses.

Apellis Pharmaceuticals reports its first profitable year on strong SYFOVRE and EMPAVELI sales, but faces pressure to maintain momentum amid competition.

A new report shows patients are rejecting 'overdone' looks for subtle, strategic care, driven by Ozempic, menopause, and a desire for authenticity.